KIAA0753 gene
Bayer’s Kerendia Demonstrates 16% Reduction in Cardiovascular Risk for Heart Failure Patients
Bayer, Kerendia, cardiovascular risk, heart failure, finerenone, Phase III trial, FINEARTS-HF, MOONRAKER
Actionable Insights Powered by AI
Bayer, Kerendia, cardiovascular risk, heart failure, finerenone, Phase III trial, FINEARTS-HF, MOONRAKER